이엔셀

456070KOSDAQ기초 의약물질 제조업

44.3 / 100

Reference Date: 2026-07-24

Financial Score10.0 / 40

News Sentiment21.3 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Plunged 18.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

InCell operates two business models based on its GMP technology for cell and gene therapy drug development: CDMO (Contract Development and Manufacturing Organization) for advanced biopharmaceuticals and the development of next-generation cell and gene therapy drugs. The company holds the only GMP facility in South Korea capable of simultaneous cell and virus production, focusing on therapies for rare diseases like Charcot-Marie-Tooth and Duchenne muscular dystrophy.

Number of Employees

112people

Average Salary

42.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 25.444.0Point

PBR

1.80Industry Average 1.262.5Point

Higher than industry avg (caution)

ROE

-36.79Industry Average -6.033.5Point

6.1x industry avg (excellent)

Debt Ratio

53.53Industry Average 6.620.0Point

8.1x industry avg (risky)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼27.1% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼14.2% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -36.0% (declining, 2yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
이엔셀, 엘병원과 첨단재생의료 업무협약
이엔셀과 엘병원의 협력으로 세포·유전자치료제 분야에서의 연구 및 임상 개발이 가속화되어 긍정적인 시장 반응 예상.
Positive
이엔셀, CMT1A 임상 2a상 3개 기관 투여 본격화
이엔셀의 CMT1A 치료제 EN001 임상 2a상 다기관 투여 시작으로 긍정적인 임상 진행 신호.
Positive
이엔셀, 바이오USA서 글로벌 20개사와 파트너링 논의
이엔셀은 바이오USA에서 글로벌 파트너들과의 협력 논의를 통해 임상 결과의 긍정적인 CMTNSv2 점수 감소를 공유하며 해외 개발 협력 기회를 모색하여 긍정적인 시장 반응을 얻고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 6,440Won52-week high 20,15052-week low 5,860

1-month return0.0Point

1m -17.96% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral전환가액의조정 (제1회차)2026-07-13
Neutral[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) (샤르코마리투스(CharcotMarieTooth disease, CMT) 1A형 환자를 대상으로 EN001의 유효성 및 안전성을 평가하기 위해 1b/2a상 임상시험계획 변경승인)2026-07-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-25